JP2021525719A5 - - Google Patents
Info
- Publication number
- JP2021525719A5 JP2021525719A5 JP2020566286A JP2020566286A JP2021525719A5 JP 2021525719 A5 JP2021525719 A5 JP 2021525719A5 JP 2020566286 A JP2020566286 A JP 2020566286A JP 2020566286 A JP2020566286 A JP 2020566286A JP 2021525719 A5 JP2021525719 A5 JP 2021525719A5
- Authority
- JP
- Japan
- Prior art keywords
- fucα1
- antigen
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023169604A JP7696404B2 (ja) | 2018-05-31 | 2023-09-29 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678890P | 2018-05-31 | 2018-05-31 | |
| US62/678,890 | 2018-05-31 | ||
| PCT/US2019/034708 WO2019232246A1 (en) | 2018-05-31 | 2019-05-30 | Therapeutic antibodies binding to biantennary lewis b and lewis y antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023169604A Division JP7696404B2 (ja) | 2018-05-31 | 2023-09-29 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525719A JP2021525719A (ja) | 2021-09-27 |
| JP2021525719A5 true JP2021525719A5 (enExample) | 2023-01-11 |
| JP7360401B2 JP7360401B2 (ja) | 2023-10-12 |
Family
ID=66952044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566286A Active JP7360401B2 (ja) | 2018-05-31 | 2019-05-30 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
| JP2023169604A Active JP7696404B2 (ja) | 2018-05-31 | 2023-09-29 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023169604A Active JP7696404B2 (ja) | 2018-05-31 | 2023-09-29 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11440967B2 (enExample) |
| EP (1) | EP3802604A1 (enExample) |
| JP (2) | JP7360401B2 (enExample) |
| KR (1) | KR102480815B1 (enExample) |
| CN (1) | CN112533948B (enExample) |
| AU (1) | AU2019278875B2 (enExample) |
| BR (1) | BR112020023380A2 (enExample) |
| CA (1) | CA3106380A1 (enExample) |
| IL (1) | IL279109B2 (enExample) |
| MX (1) | MX2020011385A (enExample) |
| SG (1) | SG11202010025YA (enExample) |
| TW (1) | TWI842712B (enExample) |
| WO (1) | WO2019232246A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3802604A1 (en) * | 2018-05-31 | 2021-04-14 | Glyconex Inc. | Therapeutic antibodies binding to biantennary lewis b and lewis y antigens |
| CN120025447A (zh) * | 2023-11-23 | 2025-05-23 | 广东菲鹏制药股份有限公司 | 抗人pvrig抗体及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| IL94872A (en) | 1989-06-30 | 1995-03-30 | Oncogen | Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| JPH0693A (ja) * | 1992-04-23 | 1994-01-11 | Otsuka Pharmaceut Co Ltd | モノクローナル抗体 |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5792456A (en) | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US6323039B1 (en) | 1999-06-22 | 2001-11-27 | Mitokor | Compositions and methods for assaying subcellular conditions and processes using energy transfer |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| GB0111628D0 (en) | 2001-05-11 | 2001-07-04 | Scancell Ltd | Binding member |
| WO2005028515A1 (ja) | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| KR20090039739A (ko) * | 2006-08-03 | 2009-04-22 | 아스트라제네카 아베 | αＶβ６에 대해 작용하는 항체 및 그의 용도 |
| US20100040620A1 (en) | 2006-09-20 | 2010-02-18 | Linda Gillian Durrant | ANTI-CANCER ANTIBODIES AGAINST LEWISy AND LEWISb ANTIGENS |
| AU2007334264A1 (en) * | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to BTLA and methods of use |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| WO2012032181A2 (en) | 2010-09-10 | 2012-03-15 | Allozyne, Inc | Novel antibody derivatives |
| WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| JP2016509582A (ja) | 2012-12-19 | 2016-03-31 | アンプリミューン， インコーポレイテッド | 抗ヒトｂ７−ｈ４抗体およびその使用 |
| CN113698488A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| EP3802604A1 (en) * | 2018-05-31 | 2021-04-14 | Glyconex Inc. | Therapeutic antibodies binding to biantennary lewis b and lewis y antigens |
-
2019
- 2019-05-30 EP EP19731849.6A patent/EP3802604A1/en active Pending
- 2019-05-30 CA CA3106380A patent/CA3106380A1/en active Pending
- 2019-05-30 MX MX2020011385A patent/MX2020011385A/es unknown
- 2019-05-30 IL IL279109A patent/IL279109B2/en unknown
- 2019-05-30 WO PCT/US2019/034708 patent/WO2019232246A1/en not_active Ceased
- 2019-05-30 CN CN201980036582.XA patent/CN112533948B/zh active Active
- 2019-05-30 BR BR112020023380-3A patent/BR112020023380A2/pt unknown
- 2019-05-30 JP JP2020566286A patent/JP7360401B2/ja active Active
- 2019-05-30 US US16/427,146 patent/US11440967B2/en active Active
- 2019-05-30 AU AU2019278875A patent/AU2019278875B2/en active Active
- 2019-05-30 SG SG11202010025YA patent/SG11202010025YA/en unknown
- 2019-05-30 KR KR1020207035837A patent/KR102480815B1/ko active Active
- 2019-05-31 TW TW108119035A patent/TWI842712B/zh active
-
2022
- 2022-07-26 US US17/815,117 patent/US11643471B2/en active Active
-
2023
- 2023-02-28 US US18/175,905 patent/US20240067746A1/en active Pending
- 2023-09-29 JP JP2023169604A patent/JP7696404B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112574307B (zh) | 抗人Claudin18.2抗体及其应用 | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| JP2019527553A5 (enExample) | ||
| JP2021516051A5 (enExample) | ||
| TWI777056B (zh) | 結合至ssea4的單株抗體及其用途 | |
| JP2022512132A5 (enExample) | ||
| JP2019116474A5 (enExample) | ||
| JP2011526493A5 (enExample) | ||
| CN110066336B (zh) | 抗cd47单克隆抗体、片段及其医药用途 | |
| JP2020534830A5 (enExample) | ||
| JP2018505681A5 (enExample) | ||
| FI3310812T3 (fi) | Anti-her2-vasta-aineita ja käyttömenetelmiä | |
| JP2012519492A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2023520969A5 (enExample) | ||
| JP2021512604A5 (enExample) | ||
| JP2015508056A5 (enExample) | ||
| CN116813788B (zh) | 一种结合依托咪酯的抗体及其应用 | |
| JP2021530244A5 (enExample) | ||
| JP2024001073A5 (enExample) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| CN112094348B (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| JP2021529524A5 (enExample) | ||
| JP2024521701A5 (enExample) | ||
| CN120129701A (zh) | 抗ccr8的抗体及其用途 |